Information for scientists

ME/CFS Lines - Cohort and Biobank

In the ME/CFS Lines consortium, several national and international research partners develop biomedical research on ME/CFS. This consortium uses data and biomaterials collected since 2006 in the Lifelines population cohort, which includes over 167,000 participants.

Approach

The DePaul Symptom Questionnaire (DSQ-2) and diagnostic tests are used to identify ME/CFS patients within Lifelines. Biomaterials are used to map genetics, microbiome, antibody repertoire, proteome and metabolome in ME/CFS patients and matched controls.

The emphasis is on a multi-omics approach, for which biomaterials from before the onset of ME/CFS are also available. With these data, researchers within this consortium will search for new mechanisms that may explain the onset of ME/CFS, in order to achieve better diagnosis and treatment.

Timeline

DEC-2023 to JAN-2024
DSQ-2 to all adult participants

JAN-2024 to OCT-2024
Pre-selection of ME/CFS Lines cohort and preparation data collection

NOV-2024 to JUL-2025
Collection of diagnostic data and biomaterials

2025-2027
Analysis of biomaterials for mechanistic studies

Data and Biomaterials

Being integrated in Lifelines infrastructure, in the ME/CFS Lines cohort all the data collected by Lifelines are available, including repeated assessments of:

  • Cardiovascular function (ECG, blood pressure)
  • Cognitive functioning
  • Lung function (spirometry)
  • Anthropometry
  • Psychiatric interview
  • Biomaterials (blood, urine, feces)

In addition, specifically for ME/CFS patients and matched controls, ME/CFS Lines will collect:

  • Genetics
  • Microbiome
  • antibody repertoire (PhipSeq)
  • Proteome (OLink)
  • Metabolome

Funding opportunities

ZonMw has recently announced a new round of funding withing the ME/CFS program, for new biomedical research projects to join one of the existing consortia:

  • ME/CFS Lines
  • NMCB

Projects

Antilichamen

Het immuunsysteem, of afweersysteem, verdedigt ons lichaam tegen indringers zoals virussen en bacteriën. Er zijn aanwijzingen dat verstoorde immuunresponsen betrokken zijn bij ME/CVS.

Post-Exertionele Malaise (PEM)

Patiënten met ME/CVS ervaren dat inspanning hun symptomen verergert en dat ze hier lange tijd last van hebben. Dit heet post-exertionele malaise (PEM)

Darmmicrobioom

Met het darmmicrobioom bedoelen we micro-organismen zoals bacteriën, schimmels en virussen die in de darmen leven.

Erfelijke aanleg

Het krijgen van ME/CVS wordt mogelijk voor 48-56% bepaald door iemands erfelijke aanleg oftewel genetische (DNA) achtergrond.

Partners

Lifelines Erasmus MC MU Vienna Pluut & Partners TU Delft ME/CVS Stichting Rijkuniversiteit Groningen UMCG ZonMw